Benjamin Williams's Contact Details

Benjamin Williams's Company Details

4M Therapeutics Inc.

Princeton, New Jersey, United States • 4 Employees
Research

4MTx is developing small molecules to treat neuropsychiatric disorders by enhancing neuroplasticity and reducing neuro-inflammation. Here are some highlights: - 4MTx has a revolutionary neuroscience platform. Stem cells derived from an adult are induced to develop into neural progenitor cells, which are used for high throughput screening (HTS) and lead optimization. - Using this platform, we performed HTS on over 325,000 compounds and identified several small molecules that are potent and selective WNT enhancers that cross the blood brain barrier. - Using traditional techniques, it can take many years and extensive investment to develop small molecules with this profile. Several 4MTx compounds already have this profile and may be only two years from clinical trials. - Our initial focus will be the treatment of bipolar disorder and late-onset Alzheimer's disease where the WNT pathway has in vitro, in vivo, clinical, and genetic validation. Given the potency and selectivity of our small molecules -- and the growing evidence of the importance of the WNT pathway in other neuropsychiatric and neurological disorders -- we have a "platform-in-a-molecule" opportunity. - Our scientific founders are world-leaders in chemistry, neurobiology, and the pharmacology of neuroplasticity at Harvard, MIT, and the University of Washington. Our CEO has 25 years of industry experience and a track record of successful drug approvals.